Navigation Links
Bayer Issues Additional Guidance to Physicians on Trasylol(R)
Date:10/25/2007

LEVERKUSEN, Germany and WEST HAVEN, Conn., Oct. 25 /PRNewswire/ -- Today Bayer announced new guidance to physicians and health care providers regarding the use of Trasylol(R) (aprotinin injection) in patients at an increased risk of blood loss and blood transfusion undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).

The company did so after being notified that the BART Executive Committee had halted the Canadian-based trial -- a randomized, controlled trial being conducted in high-risk cardiac surgery patients. This followed a letter from the BART Data Safety Monitoring Board informing the Committee that a planned periodic data analysis indicated reduced bleeding but also an increase in all-cause mortality (that almost reached conventional statistical significance for 30-day mortality) for patients in the aprotinin treatment arm compared to patients who received either aminocaproic acid or tranexamic acid. Data have not, as yet, been shared with Bayer.

Bayer immediately informed the U.S. Food and Drug Administration (FDA), Health Canada and other health authorities around the world.

Bayer has also been informed that data will now be collected from all centers throughout Canada and data analysis will be undertaken by those conducting the BART study -- a process that is expected to take between four and eight weeks. Consequently no further evaluation either by Bayer or by regulatory authorities can take place until additional information becomes available from the BART investigators.

Guidance from Bayer includes a recommendation that physicians use Trasylol only in accordance with approved product labeling. Trasylol is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.

Additionally
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. FDA Issues Safety Alert on Avandia
4. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
5. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
8. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
9. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
10. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
11. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
(Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
(Date:7/30/2014)... , 30. Juli 2014 Die ... führender Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, ... Landgerichts München in Deutschland anfechten werden. Dieses ... Masken ein Patent von ResMed verletze. Apex ... wichtigen Ländern gegen verschiedene Patente von ResMed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Near-Complete Mitigation of Choroidal,Neovascularization (CNV) in an AMD ... Lpath, Inc. ,the category leader in therapeutic agents ... standard animal,model of human age-related macular degeneration (AMD). ... meeting of the,Association of Research in Vision and ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Cached Medicine Technology:Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
(Date:7/30/2014)... (PRWEB) July 30, 2014 It is said ... proved this to be true as a product sponsor ... in Las Vegas this past June. , Lash Affair ... and overall success of the eyelash industry through collaboration so ... proud to have supported NEESA ’s event. Lash Affair’s ...
(Date:7/30/2014)... mutation linked to obesity respond differently to pictures of ... not have the genetic mutation, according to a new ... Clinical Endocrinology & Metabolism ( JCEM ). , ... results from a combination of eating too much, getting ... of appetizing foods that are high in calories can ...
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 The ... (2013-18)” provides an insight into the market dynamics and ... report covers the actual and forecasted market sizing of ... various factors fuelling the demand of the same. It ... segment and major players in the market. Further, the ...
(Date:7/30/2014)... July 30, 2014 Dialogic ... today announced that DollarPhone, the largest privately owned ... the Dialogic® ControlSwitch™ softswitch to offer ... number portability (LNP) to both its wholesale and ... ControlSwitch is able to power DollarPhone’s network infrastructure, ...
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July ... might set the stage for harmful health habits, including eating ... conducted from 1982 to 2012 also found a link between ... younger a woman was when she started her first diet, ... control behaviors -- like vomiting or laxative misuse," said study ...
Breaking Medicine News(10 mins):Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Brain response to appetizing food cues varies among obese people 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3
... analysis of records of pancreatic surgery during the last ... pancreatic cancer surgeon// Charles J. Yeo, M.D., Samuel D. ... College of Thomas Jefferson University and Thomas Jefferson University ... his colleagues have revealed that contrary to what many ...
... major intestinal surgery, including stomach reduction for obesity, may ... results of the study have been published in the ... findings on three patients with increasingly poor eyesight or ... the space of a year. None of the patients ...
... A number of Canadians are more obese ... smoking less, according to a new national health survey// . ... Canada, on Tuesday, revealed that there was an underestimation ... by approximately nine per cent. The survey also indicated ...
... that a man is very critical and is suspected to have ... in a Shenzhen hospital. It is very evident that the virus ... Health Protection said that the victim lives in Shenzhen and is ... residing in Shenzhen. He fell ill after he visited a wet ...
... Families who fear the transfer of genetic diseases to their progeny ... a major NHS bank of babies' stem cells//. ,Stem ... to treat diseases such as leukemia. However cord blood banking has ... public as well as clinicians, wherein blood is taken from the ...
... warn the number of New Zealanders who take party pills ... authorities argued taking// party pills escape people from taking drugs. ... used the pill atleast once – says researchers commissioned by ... physical and psychological parts such as sleeplessness, loss of appetite, ...
Cached Medicine News:Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 2Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 3Health News:Incidence Of Smoking Less, Obesity More, in Canada: StatsCan 2Health News:Bank of Stem Cells to Give Hope to Sick Children 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... effective upgrade path that allows users to ... modularity. The potential to combine two units ... a single stimulating coil. The ability to ... the power level of each Magstim 200 ...
... The Magstim Model 200 uses a ... otherwise inaccessible nerves. World market leader in ... developed by the University of Sheffield in ... cortical hemispheric and peripheral stimulation. Our best ...
Medicine Products: